Seminars in Oncology
Volume 33 , Pages 8-12 , April 2006

Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial

  • Paul E. Goss

      Affiliations

    • Dr Goss has served as a member of an advisory board for Novartis, Pfizer and Astra-Zeneca. He has received honoraria from Novartis, Pfizer and Astra-Zeneca.
    • Corresponding Author InformationAddress correspondence and reprint requests to Paul E. Goss, MD, PhD, Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Room 640, Boston, MA 02114.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00173-4

doi: 10.1053/j.seminoncol.2006.03.025

Seminars in Oncology
Volume 33 , Pages 8-12 , April 2006

Article Tools

* Image Usage & Resolution